MX349662B - Anticuerpos de antigenos antitumorales y metodos de uso. - Google Patents

Anticuerpos de antigenos antitumorales y metodos de uso.

Info

Publication number
MX349662B
MX349662B MX2013000853A MX2013000853A MX349662B MX 349662 B MX349662 B MX 349662B MX 2013000853 A MX2013000853 A MX 2013000853A MX 2013000853 A MX2013000853 A MX 2013000853A MX 349662 B MX349662 B MX 349662B
Authority
MX
Mexico
Prior art keywords
methods
tumor antigen
antigen antibodies
antibodies
associated antigen
Prior art date
Application number
MX2013000853A
Other languages
English (en)
Other versions
MX2013000853A (es
Inventor
D Marks James
Zhou Yu
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Publication of MX2013000853A publication Critical patent/MX2013000853A/es
Publication of MX349662B publication Critical patent/MX349662B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y30/00—Nanotechnology for materials or surface science, e.g. nanocomposites
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2884—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD44
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Cell Biology (AREA)
  • Composite Materials (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Condensed Matter Physics & Semiconductors (AREA)
  • General Physics & Mathematics (AREA)
  • Materials Engineering (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a los anticuerpos que se unen al antígeno CD44 asociado a tumores o al antígeno EphA2 asociado a tumores, así como composiciones relacionadas y métodos. Los métodos de uso comprenden terapias, diagnósticos y métodos de análisis para el cáncer.
MX2013000853A 2010-07-22 2011-07-22 Anticuerpos de antigenos antitumorales y metodos de uso. MX349662B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36682310P 2010-07-22 2010-07-22
PCT/US2011/045069 WO2012012759A2 (en) 2010-07-22 2011-07-22 Anti-tumor antigen antibodies and methods of use

Publications (2)

Publication Number Publication Date
MX2013000853A MX2013000853A (es) 2013-06-28
MX349662B true MX349662B (es) 2017-08-08

Family

ID=45497493

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013000853A MX349662B (es) 2010-07-22 2011-07-22 Anticuerpos de antigenos antitumorales y metodos de uso.

Country Status (11)

Country Link
US (3) US9220772B2 (es)
EP (1) EP2595657A4 (es)
KR (1) KR20130048242A (es)
CN (2) CN106432495A (es)
AU (1) AU2011280893C1 (es)
BR (1) BR112013001640A2 (es)
CA (1) CA2806076A1 (es)
MX (1) MX349662B (es)
RU (1) RU2598711C2 (es)
WO (1) WO2012012759A2 (es)
ZA (1) ZA201300573B (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX342271B (es) 2005-05-18 2016-09-21 Ablynx Nv Nanobodiestm (nanocuerpos) mejorados contra el factor alfa de necrosis del tumor.
US8598321B2 (en) 2007-03-22 2013-12-03 The Regents Of The University Of California Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
CA2732003A1 (en) 2008-07-31 2010-02-04 James D. Marks Antibodies that neutralize botulinum neurotoxins
US9243057B2 (en) 2010-08-31 2016-01-26 The Regents Of The University Of California Antibodies for botulinum neurotoxins
WO2013158803A1 (en) 2012-04-17 2013-10-24 Merrimack Pharmaceuticals, Inc. Compositions and methods for non-invasive imaging
US9717724B2 (en) 2012-06-13 2017-08-01 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies
AU2013202947B2 (en) 2012-06-13 2016-06-02 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
ES2446215B1 (es) * 2012-08-06 2015-04-01 Consejo Superior De Investigaciones Científicas (Csic) Aplicación terapéutica de agentes inhibidores de cd44 frente a la leucemia linfoblástica aguda (all) humana.
CN104231080B (zh) * 2013-03-15 2019-07-02 中国医学科学院药物研究所 全人源抗人白介素17a单链抗体
KR102553717B1 (ko) * 2013-08-26 2023-07-11 바이오엔테크 리서치 앤드 디벨롭먼트 인코포레이티드 시알릴-루이스 ａ에 대한 사람 항체 코드화 핵산
WO2015061592A1 (en) * 2013-10-23 2015-04-30 Merrimack Pharmaceuticals, Inc. Liposomes for non-invasive imaging and drug delivery
AU2015287749B2 (en) * 2014-07-11 2021-03-11 The Regents Of The University Of California Tumor selective macropinocytosis-dependent rapidly internalizing antibodies
WO2016014576A1 (en) * 2014-07-21 2016-01-28 Novartis Ag Treatment of cancer using a cd33 chimeric antigen receptor
WO2016025884A1 (en) * 2014-08-14 2016-02-18 The Trustees Of The University Of Pennsylvania Glycosyl-phosphatidylinositol (gpi)-linked gdnf family alpha-receptor 4 (gfralpha4)-specific antibody and uses thereof
JP2017525710A (ja) 2014-08-22 2017-09-07 ソレント・セラピューティクス・インコーポレイテッドＳｏｒｒｅｎｔｏ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． Ｃｘｃｒ５に結合する抗原結合タンパク質
EP3221351A4 (en) * 2014-11-19 2018-06-27 Memorial Sloan-Kettering Cancer Center Methods and compositions for cancer treating conditions relating to over expressions of epha2
CN107922484A (zh) * 2015-03-06 2018-04-17 索伦托治疗有限公司 结合tim3的抗体治疗剂
US11318131B2 (en) 2015-05-18 2022-05-03 Ipsen Biopharm Ltd. Nanoliposomal irinotecan for use in treating small cell lung cancer
CN106699888B (zh) * 2015-07-28 2020-11-06 上海昀怡健康科技发展有限公司 一种pd-1抗体及其制备方法和应用
EP3337467B1 (en) 2015-08-20 2020-12-09 Ipsen Biopharm Ltd. Combination therapy using liposomal irinotecan and a parp inhibitor for cancer treatment
IL257149B1 (en) 2015-08-21 2024-07-01 Ipsen Biopharm Ltd Methods for treating pancreatic cancer metastases using combined treatments including liposomal irinotecan and oxaliplatin
AU2017230091B2 (en) 2016-03-10 2022-04-07 Acceleron Pharma Inc. Activin type 2 receptor binding proteins and uses thereof
CA3016383A1 (en) * 2016-03-16 2017-09-21 Merrimack Pharmaceuticals, Inc Treating ephrin receptor a2 (epha2) positive cancer with targeted docetaxel-generating nano-liposome compositions
BR112018015898A2 (pt) * 2016-03-16 2019-01-22 Merrimack Pharmaceuticals Inc polipeptídeos de ligação de proteína a, anticorpos anti-epha2 e métodos de utilização dos mesmos
CN109310782A (zh) * 2016-03-16 2019-02-05 梅里麦克制药股份有限公司 肝配蛋白受体A2(EphA2)靶向性的多西他赛生成纳米脂质体组合物
AU2017232634A1 (en) * 2016-03-16 2018-09-13 Merrimack Pharmaceuticals, Inc Nanoliposomal Targeting of Ephrin Receptor A2 (Epha2) And Related Diagnostics
BR112019007844A2 (pt) 2016-11-02 2019-07-16 Ipsen Biopharm Ltd tratamento de câncer gástrico usando terapias de combinação compreendendo irinotecano lipossômico, oxaliplatina, 5-fluoroacila (e leucovorina)
MA46952A (fr) 2016-12-01 2019-10-09 Regeneron Pharma Anticorps anti-pd-l1 radiomarqués pour imagerie immuno-pet
US11879014B2 (en) 2017-03-17 2024-01-23 Tusk Therapeutics Ltd. Method of treating cancer or depleting regulatory T cells in a subject by administering a human IGG1 anti-CD25 antibody
CN112020512A (zh) 2018-03-13 2020-12-01 塔斯克疗法有限公司 用于肿瘤特异性细胞清除的抗-cd25
WO2021051004A1 (en) * 2019-09-13 2021-03-18 Distributed Bio, Inc. Methods of antibody panning against target proteins
WO2022241200A1 (en) * 2021-05-14 2022-11-17 Vanderbilt University Cross-reactive coronavirus antibodies
WO2022251575A1 (en) * 2021-05-27 2022-12-01 The United States Government As Represented By The Department Of Veterans Affairs Human monoclonal antibodies specific to streptolysin o and methods of use
CN118055945A (zh) * 2021-08-06 2024-05-17 韩国生命工学研究院 新型抗epha2嵌合抗原受体和表达其的免疫细胞
WO2024010119A1 (ko) * 2022-07-07 2024-01-11 주식회사 유틸렉스 돌연변이 egfr 및 epha2를 동시 타겟하는 키메라 항원 수용체
WO2024040194A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
WO2024114404A1 (zh) * 2022-11-28 2024-06-06 成都科伦精准生物科技有限公司 特异性结合gpc3的嵌合抗原受体及其应用

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6001356A (en) * 1995-09-29 1999-12-14 Rush-Presbyterian-St. Luke's Medical Center Method of inhibiting tissue destruction in autoimmune disease using anti-CD44 antibodies
KR20060067983A (ko) 1999-01-15 2006-06-20 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
KR101155294B1 (ko) * 2000-06-16 2013-03-07 캠브리지 안티바디 테크놀로지 리미티드 면역특이적으로 ＢＬｙＳ에 결합하는 항체
US7101976B1 (en) 2000-09-12 2006-09-05 Purdue Research Foundation EphA2 monoclonal antibodies and methods of making and using same
AU3400102A (en) * 2000-12-05 2002-06-18 Alexion Pharma Inc Rationally designed antibodies
US20050152899A1 (en) 2002-05-10 2005-07-14 Kinch Michael S. EphA2 agonistic monoclonal antibodies and methods of use thereof
CA2485548A1 (en) * 2002-05-10 2004-02-19 Purdue Research Foundation Epha2 agonistic monoclonal antibodies and methods of use thereof
JP4557714B2 (ja) * 2002-05-10 2010-10-06 メディミューン，エルエルシー ＥｐｈＡ２モノクローナル抗体およびその使用法
AU2003272511A1 (en) * 2002-09-13 2004-04-30 Dyax Corporation Cd44-binding ligands
EP2368578A1 (en) 2003-01-09 2011-09-28 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
KR20060135671A (ko) * 2003-11-20 2006-12-29 메디뮨 인코포레이티드 ＥｐｈＡ２ 작동성 모노클로날 항체 및 이의 사용 방법
US20060123504A1 (en) * 2004-12-07 2006-06-08 Avigenics, Inc. Methods of producing polyclonal antibodies
US20050260710A1 (en) * 2004-03-31 2005-11-24 Sekisui Chemical Co. Ltd. Methods for producing recombinant polyclonal immunoglobulins
WO2005110474A2 (en) 2004-05-10 2005-11-24 Macrogenics, Inc. HUMANIZED FcϜRIIB SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF
US8222253B2 (en) * 2004-10-23 2012-07-17 Case Western Reserve University Peptide and small molecule agonists of EphA and their uses
WO2007024249A2 (en) 2004-11-10 2007-03-01 Macrogenics, Inc. Engineering fc antibody regions to confer effector function
PT1828249E (pt) 2004-12-03 2011-02-25 Schering Corp Biomarcadores para a pré-selecção de pacientes para terapêutica anti-igf1r
MX2007009403A (es) * 2005-02-04 2007-10-02 Raven Biotechnologies Inc Anticuerpos que se unen a epha2 y metodos para usar los mismos.
JP5628476B2 (ja) * 2005-04-28 2014-11-19 ベンタナ・メデイカル・システムズ・インコーポレーテツド 抗体コンジュゲート
JP2009506790A (ja) * 2005-09-07 2009-02-19 メディミューン，エルエルシー 毒素とコンジュゲートしたｅｐｈ受容体抗体
RU2008129827A (ru) * 2005-12-21 2010-01-27 МЕДИММЬЮН, ЭлЭлСи (US) МОЛЕКУЛЫ EphA2-BiTE И ИХ ПРИМЕНЕНИЕ
EP2076769B1 (en) 2006-10-03 2018-04-25 Genmab A/S High througput methods for characterization of antibodies
PT2199390T (pt) * 2007-08-30 2017-03-15 Daiichi Sankyo Co Ltd Anticorpo anti-epha2
EP2356270B1 (en) 2008-11-07 2016-08-24 Fabrus Llc Combinatorial antibody libraries and uses thereof
BR112018015898A2 (pt) * 2016-03-16 2019-01-22 Merrimack Pharmaceuticals Inc polipeptídeos de ligação de proteína a, anticorpos anti-epha2 e métodos de utilização dos mesmos
CN109310782A (zh) * 2016-03-16 2019-02-05 梅里麦克制药股份有限公司 肝配蛋白受体A2(EphA2)靶向性的多西他赛生成纳米脂质体组合物

Also Published As

Publication number Publication date
US20130209481A1 (en) 2013-08-15
US10406225B2 (en) 2019-09-10
CN106432495A (zh) 2017-02-22
ZA201300573B (en) 2014-03-26
AU2011280893B2 (en) 2014-12-04
US9446125B2 (en) 2016-09-20
CN103168104A (zh) 2013-06-19
WO2012012759A3 (en) 2013-04-11
AU2011280893C1 (en) 2016-02-04
BR112013001640A2 (pt) 2020-08-04
WO2012012759A2 (en) 2012-01-26
US20160376369A1 (en) 2016-12-29
AU2011280893A1 (en) 2013-03-07
US20150343081A1 (en) 2015-12-03
EP2595657A2 (en) 2013-05-29
EP2595657A4 (en) 2015-09-23
RU2013107776A (ru) 2014-08-27
MX2013000853A (es) 2013-06-28
KR20130048242A (ko) 2013-05-09
CN103168104B (zh) 2016-09-28
US9220772B2 (en) 2015-12-29
RU2598711C2 (ru) 2016-09-27
CA2806076A1 (en) 2012-01-26

Similar Documents

Publication Publication Date Title
MX349662B (es) Anticuerpos de antigenos antitumorales y metodos de uso.
MX2013004761A (es) Nuevas moleculas de union al receptor del factor de crecimiento epidermico (egfr) e inmunoconjugados de estas.
MY173839A (en) Cd37-binding molecules and immunoconjugates thereof
MX2017008819A (es) Anticuerpos anti-cd47 y usos de los mismos.
AU2011338480A8 (en) Humanized antibodies to LIV-1 and use of same to treat cancer
SG184310A1 (en) Antibodies that bind human cd27 and uses thereof
EA201201000A1 (ru) Способы лечения колоректального рака
MY160499A (en) Anti-cd38 antibodies
MX357391B (es) Anticuerpos anti-erbb3 y usos de los mismos.
MX369148B (es) Agentes de unión kir3dl2.
MX341076B (es) Formulaciones estables de anticuerpos para el receptor humano pd-1 de meurte programada y tratamientos relacionados.
SG10201902924RA (en) Antibodies that bind ebola glycoprotein and uses thereof
MX366804B (es) Translocaciones de la r-espondina y sus metodos de uso.
PH12014501164A1 (en) Anti-cd98 antibodies and methods of use thereof
IN2014KN00848A (es)
WO2012019024A3 (en) Her3-binding molecules and immunoconjugates thereof
MX2019009654A (es) Anticuerpos e inmunoconjugados del receptor 1 de folato y usos de los mismos.
MX346973B (es) Anticuerpos especificos de tumores y usos para los mismos.
MX2013010475A (es) Composiciones inmunoterapeuticas de levadura-brachyuri.
MX353476B (es) Anticuerpos anti-cxcl13 y metodos para usarlos.
EA201200999A1 (ru) Способы лечения рака молочной железы
TR201903312T4 (tr) Benralizumab kullanarak astım alevlenme oranlarini azaltma yöntemleri.
IN2014DN09717A (es)
AU2012371260A8 (en) Predicitive biomarker for cancer treatment with ADCC enhanced antibodies
MX362497B (es) Un anticuerpo que se une específicamente al receptor alfa del folato y usos del mismo.

Legal Events

Date Code Title Description
FG Grant or registration